Tyme Technologies (TYME) Reports Q2 Loss of $0.03; Cash and Cash Equivalents of $96.6M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. DMART:IN
8. NVDA
9. LDOS
10. AXP

Go back to Tyme Technologies (TYME) Reports Q2 Loss of $0.03; Cash and Cash Equivalents of $96.6M

TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results

November 8, 2021 6:50 AM EST

First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor

PanCAN Precision Promise trial to add five new sites in early 2022

Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications

Maintained a well-capitalized position, with $96.6 million in cash and marketable securities as of September 30

Company to host live conference... More